Cargando…
Effect of rosiglitazone and ramipril on macrovasculopathy in patients with type 2 diabetes: needs longer treatment and/or higher doses?
INTRODUCTION: The aim of the study is to investigate whether standard doses of rosiglitazone (4 mg/daily) and ramipril (5 mg/daily) can reverse pre-clinical macrovasculopathy in newly diagnosed never treated type 2 diabetes (T2DM) patients. METHODS: In this randomized, double-blind, placebo-controll...
Autores principales: | Rahman, Sayeeda, Ismail, Aziz Al-Shafi, Ismail, Shaiful Bhari, Naing, Nyi Nyi, Rahman, Abdul Rashid Abdul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262381/ https://www.ncbi.nlm.nih.gov/pubmed/22291490 |
Ejemplares similares
-
Treatment of diabetic vasculopathy with rosiglitazone and ramipril: Hype or hope?
por: Rahman, Sayeeda, et al.
Publicado: (2009) -
Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal
Publicado: (2011) -
The Incontinence Praying Ability and the Incontinence Quality of Life Questionnaires for Muslim Women: A Confirmatory Study of the Malay Language Versions
por: Cheng, Kueh Yee, et al.
Publicado: (2018) -
Central Corneal Thickness and Intraocular Pressure in Malay Children
por: Heidary, Fatemah, et al.
Publicado: (2011) -
Correction: Central Corneal Thickness and Intraocular Pressure in Malay Children
por: Heidary, Fatemeh, et al.
Publicado: (2011)